Stress Reduction Intervention for Women With Ischemic Heart Disease
| Status: | Terminated |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 7/21/2018 |
| Start Date: | March 6, 2018 |
| End Date: | July 6, 2018 |
Smartphone-delivered Stress Reduction Intervention for Women With Ischemic Heart Disease
This is a single center, randomized controlled trial which will include women with ischemic
heart disease to receive either a self-directed stress reduction program delivered through a
smart-phone application or activity tracking only for the first month ("early SR
intervention" and "delayed SR intervention", respectively). Patients will be monitored for 1
month for application use and step counts via telephone or email interview and/or collection
of screen-captured data. Baseline questionnaires will be repeated at the end of one month to
assess for all primary and secondary measures, at which time the control group (activity
tracking only) will be introduced to the intervention program. The early SR intervention
group will not receive a new intervention but will be encouraged to continue using the app.
Data will be collected for an additional 2 months with all participants in both groups. After
the three-month study period, the study will close with the collection of final questionnaire
data.
heart disease to receive either a self-directed stress reduction program delivered through a
smart-phone application or activity tracking only for the first month ("early SR
intervention" and "delayed SR intervention", respectively). Patients will be monitored for 1
month for application use and step counts via telephone or email interview and/or collection
of screen-captured data. Baseline questionnaires will be repeated at the end of one month to
assess for all primary and secondary measures, at which time the control group (activity
tracking only) will be introduced to the intervention program. The early SR intervention
group will not receive a new intervention but will be encouraged to continue using the app.
Data will be collected for an additional 2 months with all participants in both groups. After
the three-month study period, the study will close with the collection of final questionnaire
data.
Inclusion Criteria:
- Presence of ischemic heart disease as defined by one or more of the following within
the last 2 years:
- Positive stress test
- Admission for ACS, PCI, or CABG
- Typical or atypical ischemic symptoms within one month of enrollment
- On stable dose of anti-anginal medications for at least 2 months
- Able and willing to provide informed consent and comply with all aspects of the
protocol
- Owns a smartphone with the ability to download applications for stress reduction and
activity tracking
- English-speaking (apps are not available in other languages)
Exclusion Criteria:
- Planned for revascularization during the study period
- Self-reported or chart-reviewed diagnosis of psychotic disorder including
schizophrenia or schizoaffective disorder, bipolar disorder
- Current participation in a cardiac rehab program or planned participation during the
study period
We found this trial at
1
site
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Principal Investigator: Harmony Reynolds, MD
Phone: 212-263-7751
New York University School of Medicine NYU School of Medicine has a proud history that...
Click here to add this to my saved trials
